Neuroimmunology Program - IDIBAPS

Who we are

|Alt Image doctor|

Dr. Pablo Villoslada

Pathogenesis and Novel Therapies in Multiple Sclerosis

Current Positions

  • Director of the MS pathogenesis and therapeutics Group, IDIBAPS
  • National Coordinator of the Spanish Network of Excellence in Multiple Sclerosis (REEM), Instituto de Salud Carlos III
  • Member of the Scientific Advisory Board of the International Society of Neuroimmunology
  • Member of the Scientific Advisory Board of Multiple Sclerosis in Focus from the International Federation MS Societies
  • Member of the editorial boards of PloSONE
  • Member of the American Academy of Neurology, International Society of Neuroimmunology, American Association for the Advancement of Science, Spanish Society of Neurology, Catalan Society of Neurology

Academic Qualifications

  • Degree in Medicine and Surgery from the University of Santiago Compostela, 1990
  • Doctorate of Neurosciences from the Autonomous University of Barcelona, 1996
  • Post-doctoral Fellowship in Neuro-immunology, University of California, San Francisco, USA, 1996-97
  • Post-doctoral Fellowship in clinical neuroimmunology, Vall Hebron Hospital, Barcelona, 1998-2000

Areas of Research

Honors and Awards

  • Spanish Ministry of Health Postdoctoral Fellowship
  • Catalonian Research Foundation (FCR) Award
  • Spanish Multiple Sclerosis Foundation Award
  • Spanish Neurological Society Award for Biomedical Research in Demyelinating Diseases

Grants for Medical Research

  • Spanish Ministry of Health: Instituto de Salud Carlos III
  • TV3 Marathon Foundation, TV3, Catalonia, Spain
  • Spanish Ministry of Science and Technology
  • European Commission
  • Fundación Mutua of Madrid
  • Agency for the Administration of Universities and Research (AGAUR) of the Governement of Catalonia

Recent Selected Publications

  • M, Ros C, Martínez-Lapiscina EH, Solà-Valls N, Hervàs M, Llufriu S, La Puma D, Casals E, Blanco Y, Villoslada P, Graus F, Castelo-Branco C, Saiz A. Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Mult Scler. 2015 Sep 11. pii: 1352458515602339.
  • Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Sepúlveda M, Sola N, Saiz A, Sánchez-Dalmau B, Villoslada P, Martínez-Lapiscina EH. Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. J Neurol. 2015 Aug 11.
  • Sola-Valls N, Blanco Y, Sepúlveda M, Llufriu S, Martínez-Lapiscina EH, La Puma D, Graus F, Villoslada P, Saiz A. Walking function in clinical monitoring of multiple sclerosis by telemedicine. J Neurol. 2015 Jul;262(7):1706-13. doi: 10.1007/s00415-015-7764-x. Epub 2015 May 10.
  • Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Pérez S, Torres-Torres R, Andorra M, Llufriu S, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P. Dynamics of retinal injury after acute optic neuritis. Ann Neurol. 2015 Mar;77(3):517-28.
  • Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015 Apr 28;84(17):1805-15. doi: 10.1212/WNL.0000000000001520. Epub 2015 Apr 3. Review.
  • Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18. Review.
  • Sepúlveda M, Llufriu S, Blanco Y, Solà-Valls N, La Puma D, Berenguer J, Villoslada P, Saiz A. Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. J Neurol. 2015 Jan;262(1):219-21.
  • R, Villoslada P. The visual pathway as a model to understand brain damage in multiple sclerosis. Mult Scler. 2014 Nov;20(13):1678-85.
  • Martínez-Lapiscina EH, Fraga-Pumar E, Pastor X, Gómez M, Conesa A, Lozano-Rubí R, Sánchez-Dalmau B, Alonso A, Villoslada P. Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012. J Neurol. 2014;261(4):759-67
  • Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, Bullich S, Sepulveda M, Falcon C, Berenguer J, Saiz A, Sanchez-Dalmau B, Villoslada P. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):98-107.

More Publications Pubmed